Citations

Clear

439 citation(s) found for "Stone, M".

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis
Johnson, Janel O., Chia, Ruth , Miller, Danny E. , Kumaran, Ravindran, Abramzon, Yevgeniya, Alahmady, Nada F. , Topp, Simon , Gibbs, J. Raphael , Cookson, Mark , Sabir, Marya S. , Dalgard, Clifton L. , Troakes, Claire , Jones, Ashley R., Shatunov, Aleksey , Iacoangeli, Alfredo , Khleifat, Ahmad Al , Ticozzi, Nicola , Gellera, Cinzia , Blair, Ian P. , Dobson‐Stone, Carol , Bonkowski, Emily , Palvadeau, Robin , Tienari, Pentti J. , Morrison, Karen , Shaw, Pamela J. , Brown, Robert H., Calvo, Andrea, Al-Saif, Hind, Leigh, Fawn, Chang, Irene J. , Perlman, Seth J. , Scott, Anna I. , Başak, A. Nazlı , Landers, John E. , Crawford, Thomas O. , Smith, Bradley , Traynor, Bryan J. , Gkazi, Athina Soragia, Kenna, Kevin P., Keagle, Pamela, Tiloca, Cinzia , Vance, Caroline , King, Andrew , Pensato, Viviana , Castellotti, Barbara , Baas, Frank , Asbroek, Anneloor L.M.A. ten , McKenna‐Yasek, Diane, McLaughlin, Russell L. , Polak, Meraida , Asress, Seneshaw, Stević, Zorica, D’Alfonso, Sandra , Mazzini, Letizia, Bo, Roberto Del, Gagliardi, Stella , Querin, Giorgia, Bertolin, Cinzia , Rademakers, Rosa, Blitterswijk, Marka van , Lauria, Giuseppe, Corrado, Lucia , Sorarú, Gianni , Williams, Kelly L. , Leblond-Manry, Claire, Hardiman, Orla , Berg, Leonard H. van den, Pall, Hardev, Taroni, Franco , Wu, Zheyang , Glass, Jonathan D., Ratti, Antonia, Adeleye, Adelani, Alba, Camille , Viollet, Coralie , Bačíková, Dagmar, Hupalo, Daniel N., Pollard, Harvey B. , Martinez, Elisa McGrath, Ahmed, Sarah , Arepalli, Sampath, Baloh, Robert H. , Bowser, Robert , Campbell, Roy H. , Camu, William, Cooper‐Knock, Johnathan , Ding, Jinhui, Drory, Vivian E., Dunckley, Travis , Eicher, John D., England, Bryce, Faghri, Faraz , Feldman, Eva, Floeter, Mary Kay, Fratta, Pietro , Geiger, Joshua T. , Gibson, Summer, Hardy, John , Harms, Matthew , Heiman‐Patterson, Terry , Hernandez, Dena G., Jansson, Lilja, Kowall, Neil W. , Laaksovirta, Hannu , Landi, Francesco , Ber, Isabelle Le , Lumbroso, Serge , MacGowan, Daniel J., Maragakis, Nicholas J., Mouzat, Kévin , Murphy, Natalie A., Myllykangas, Liisa , Nalls, Mike A., Orrell, Richard W., Ostrow, Lyle W., Pickering‐Brown, Stuart , Pioro, Erik P., Pletniková, Olga , Ravits, John , Rivera, Alberto , Robberecht, Wim, Rogaeva, Ekaterina, Rollinson, Sara, Rothstein, Jeffrey D., Scholz, Sonja W. , Sendtner, Michael , Sidle, Katie, Singleton, Andrew, Smith, Nathan, Stone, David J. , Troncoso, Juan C., Valori, Miko , Damme, Philip Van , Deerlin, Vivianna M Van, Bosch, Ludo Van Den , Zinman, Lorne, Landers, John E., Chiò, Adriano, Angelocola, Stefania, Ausiello, Francesco P., Barberis, Marco, Bartolomei, Ilaria, Battistini, Stefania, Bisogni, Giulia , Borghero, Giuseppe , Brunetti, Maura, Canale, Fabrizio , Canosa, Antonio, Cantisani, Teresa A., Cardinali, Patrizio, Casale, Federico , Colletti, Tiziana , Conforti, F. L. , Conte, Amelia , Conti, Elisa, Corbo, Massimo , Cuccu, Stefania, D’Errico, Eustachio , Marco, Giovanni De , Dubbioso, Raffaele, Ferrarese, Carlo , Ferraro, Pilar M. , Floris, Gianluca , Fuda, Giuseppe, Gallone, Salvatore , Gianferrari, Giulia , Giannini, Fabio, Grassano, Maurizio, Greco, Lucia Catherine , Iazzolino, Barbara, Introna, Alessandro , Logroscino, Giancarlo , Logullo, Francesco, Lunetta, Christian , Mandich, Paola , Mandrioli, Jessica , Manera, Umberto , Manganelli, Fiore, Martinelli, Ilaria , Moglia, Cristina, Mosca, Lorena, Murru, Maria Rita, Origone, Paola , Petrelli, Cristina, Pozzi, Susanna, Pugliatti, Maura , Ricci, Claudia , Riolo, Giulia , Russo, Massimo, Salamone, Paolina, Salivetto, Marco, Salvi, Fabrizio, Santarelli, Marialuisa, Sbaiz, Luca, Sideri, Riccardo , Simonini, Cecilia , Tanel, Raffaella , Tedeschi, Gioacchino, Ticca, Anna, Torriello, Antonella, Tranquilli, Stefania, Tremolizzo, Lucio , Vasta, Rosario , Vacchiano, Veria, Volanti, Paolo , Zollino, Marcella , Lauria, Giuseppe , Ratti, Antonia , Ostrow, Lyle W. , Fratta, Pietro , Chia, Ruth , Logroscino, Giancarlo , van Blitterswijk, Marka , Scholz, Sonja W , Van Den Bosch, Ludo , Van Damme, Philip , Hardy, John , Fratta, Pietro , Fratta, Pietro , Troakes, Claire , Hardiman, Orla , Dalgard, Clifton L , Myllykangas, Liisa , Li, Rachel , Renton, Alan , Jones, Ashley R., Silani, Vincenzo , Kwok, John B. , Al‐Chalabi, Ammar , Calvo, Andrea , Mora, Gabriele , Gotkine, Marc , Glass, Ian A. , Shaw, Christopher E. , Chiò, Adriano , Fallini, Claudia , Gkazi, Soragia Athina , Scotter, Emma L. , Kenna, Kevin Patrick , Keagle, Pamela , Colombrita, Claudia , Asress, Seneshaw, Esteban‐Pérez, Jesús , Mazzini, Letizia , Comi, Giacomo P. , Ceroni, Mauro , Rheenen, Wouter van , Rademakers, Rosa , Duga, Stefano , Corti, Stefania Paola , Cereda, Cristina , Nicholson, Garth A. , Rouleau, Guy Armand , Veldink, Jan H. , Berg, Leonard H. van den , Turner, Martin R. , Talbot, Kevin , García‐Redondo, Alberto , Adeleye, Adelani, Soltis, Anthony R. , Sukumar, Gauthaman , Wilkerson, Matthew D. , Brady, Christopher B. , Brice, Alexis , Broach, James R , Campbell, Roy H., Ding, Jinhui , Drepper, Carsten , Gerhard, Glenn S. , Harms, Matthew B. , Hernandez, Dena G., Kirby, Janine , Landeck, Natalie , Maragakis, Nicholas J. , Pamphlett, Roger , Pliner, Hannah A. , Pulst, Stefan M. , Rothstein, Jeffrey D. , Simmons, Zachary , Singleton, Andrew , Smith, Nathan, Troncoso, Juan C. , Deerlin, Vivianna M. Van , Zinman, Lorne , Ausiello, Francesco Pio, Barberis, Marco , Battistini, Stefania , Bersano, Enrica , Brunetti, Maura , Cabona, Corrado , Canosa, Antonio , Capasso, Margherita , Caponnetto, Claudia , Carrera, Paola , Bella, Eleonora Dalla , Dubbioso, Raffaele , Filippi, Massimo , Fini, Nicola , Grassano, Maurizio , Iazzolino, Barbara, Bella, Vincenzo La , Lattante, Serena , Liguori, Rocco , Manganelli, Fiore , Marangi, Giuseppe , Marinou, Kalliopi , Marrosu, Maria Giovanna , Messina, Sonia , Moglia, Cristina , Mosca, Lorena, Passaniti, Carla , Petrucci, Antonio , Quattrini, Angelo , Riva, Nilo , Russo, Massimo, Sabatelli, Mario , Salamone, Paolina , Simone, Isabella Laura , Spataro, Rossella , Tedeschi, Gioacchino , Trojsi, Francesca , Vacchiano, Veria , Vita, Giuseppe , Zucchi, Elisabetta

Mayo Clinic

JAMA Neurology | August 30, 2021 | Volume: 78 | Issue: 10 | Pages: 1236

10.1001/jamaneurol.2021.2598 | PMID 34459874 Get It

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Wang, Victoria , Hanson, Curtis A. , Tschumper, Renee C. , Lesnick, Connie , Braggio, Esteban , Paietta, Elisabeth , Leis, José F., Zhang, Cong Christine, Coutré, Steven , Cashen, Amanda F. , Mato, Anthony R. , Singh, Avina K., Mullane, Michael P., Stone, Richard M. , Litzow, Mark R. , Tallman, Martin S. , Shanafelt, Tait D. , Lesnick, Connie E, Leis, Jose Francisco, Barr, Paul M , Erba, Harry Paul , Litzow, Mark R. , Kay, Neil E , Shanafelt, Tait D , Braggio, Esteban , O’Brien, Susan , Barrientos, Jacqueline C. , Barr, Paul M. , Kay, Neil E.

Mayo Clinic

Blood | August 18, 2021 | Volume: 138 | Issue: 26 | Pages: 2810-2827

10.1182/blood.2020010146 | PMID 34407545 Get It

Abstract E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL. We describe measurable residual disease (MRD) levels in E1912 over time and correlate them with clinical outcome. Undetectable MRD rates (<1 CLL cell per 104 leukocytes) were 29.1%, 30.3%, 23.4%, and 8.6% at 3, 12, 24, and 36 months for FCR, and significantly lower at 7.9%, 4.2%, and 3.7% at 12, 24, and 36 months for IR, respectively. Undetectable MRD at 3, 12, 24, and 36 months was associated with longer progression-free survival (PFS) in the FCR arm, with hazard ratios (MRD detectable/MRD undetectable) of 4.29 (95% confidence interval [CI], 1.89-9.71), 3.91 (95% CI, 1.39-11.03), 14.12 (95% CI, 1.78-111.73), and not estimable (no events among those with undetectable MRD), respectively. In the IR arm, patients with detectable MRD did not have significantly worse PFS compared with those in whom MRD was undetectable; however, PFS was longer in those with MRD levels <10−1 than in those with MRD levels above this threshold. Our observations provide additional support for the use of MRD as a surrogate end point for PFS in patients receiving FCR. In patients on indefinite ibrutinib-based therapy, PFS did not differ significantly by undetectable MRD status, whereas those with MRD <10−1 tended to have longer PFS, although continuation of ibrutinib would very likely be necessary to maintain treatment efficacy.
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William , Kohlschmidt, Jessica, Mrózek, Krzysztof , Carroll, Andrew J. , Eisfeld, Ann-Kathrin, Kolitz, Jonathan E. , Thakuri, Mohan C., Sutamtewagul, Grerk , Vij, Ravi , Byrd, John C. , Bloomfield, Clara D. , Stone, Richard M. , Byrd, John C. , Jacobson, Sawyer , Sutamtewagul, Grerk , Larson, Richard A , Stock, Wendy , Eisfeld, Ann‐Kathrin , Wang, Eunice S. , Stuart, Robert K. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 12, 2021 | Volume: 5 | Issue: 13 | Pages: 2775-2787

10.1182/bloodadvances.2021004233 | PMID 34251414 Get It

Abstract Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age <70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.
The T-Tilt Position: A Novel Modified Patient Position to Improve Stone-Free Rates in Retrograde Intrarenal Surgery
Liaw, Christine , Khusid, Johnathan A. , Gallante, Blair , Bamberger, Jake N., Atallah, William , Gupta, Mantu , Liaw, Christine W.

Mayo Clinic

Journal of Urology | July 12, 2021 | Volume: 206 | Issue: 5 | Pages: 1232-1239

10.1097/ju.0000000000001948 | PMID 34251886 Get It

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Gorelik, Mark , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1061-1070

10.1002/acr.24633 | PMID 34235889 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1071-1087

10.1002/acr.24632 | PMID 34235871 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa
Gorelik, Mark , Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1384-1393

10.1002/art.41776 | PMID 34235883 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN). Methods Twenty‐one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non–hepatitis B–related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long‐term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted. Conclusion These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Husainat, Nedaa , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann, Dua, Anisha B. , James, Karen E.

Mayo Clinic

Arthritis Care & Research | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1088-1105

10.1002/acr.24634 | PMID 34235880 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Maz, Mehrdad , Abril, Andy , Langford, Carol A. , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Maz, Mehrdad , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1349-1365

10.1002/art.41774 | PMID 34235884 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Methods Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. Conclusion These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Langford, Carol A. , Maz, Mehrdad , Abril, Andy , Gorelik, Mark , Archer, Amy M., Conn, Doyt L. , Full, Kathy A., Grayson, Peter C. , Ibarra, Maria, Imundo, Lisa F., Kim, Susan , Rhee, Rennie L. , Stone, John H. , Sule, Sangeeta , Vitobaldi, Omar I., Warner, Ann, Byram, Kevin , Dua, Anisha B. , Husainat, Nedaa , James, Karen , Kalot, Mohamad A. , Lin, Yih Chang, Springer, Jason , Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S. , Maz, Mehrdad , Conn, Doyt L , Grayson, Peter C , Merkel, Peter A , Rhee, Rennie L , Stone, John H , Sule, Sangeeta , Husainat, Nedaa M , Kalot, Mohamad A , Springer, Jason M , Turner, Amy S , Mustafa, Reem A , Dua, Anisha B , Chung, Sharon A. , Guyatt, Gordon , Merkel, Peter A. , Seo, Philip , Sundel, Robert P. , Warner, Ann

Mayo Clinic

Arthritis & Rheumatology | July 8, 2021 | Volume: 73 | Issue: 8 | Pages: 1366-1383

10.1002/art.41773 | PMID 34235894 Get It

Objective To provide evidence‐based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody–associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Methods Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel. Results We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low‐quality evidence supporting the recommendations. Conclusion This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases.